Sotorasib
Brand name: Lumakras
Rank #413 of 500 drugs by total cost
$21.3M
Total Cost
1,188
Total Claims
$21.3M
Total Cost
82
Prescribers
$18K
Cost per Claim
0
Beneficiaries
1,188
30-Day Fills
$259K
Avg Cost/Provider
14
Avg Claims/Provider
About Sotorasib
Sotorasib (sold as Lumakras) was prescribed 1,188 times by 82 Medicare Part D providers in 2023, costing the program $21.3M. At $18K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 410 | Teprotumumab-Trbw (Tepezza) | $21.4M | 389 |
| 411 | Nystatin (Nystatin) | $21.4M | 908,177 |
| 412 | Desvenlafaxine Succinate (Desvenlafaxine Succinate Er) | $21.3M | 257,580 |
| 413 | Sotorasib (Lumakras) | $21.3M | 1,188 |
| 414 | Ibuprofen (Ibuprofen) | $21.2M | 2,537,634 |
| 415 | Lubiprostone (Lubiprostone) | $21.1M | 86,987 |
| 416 | Omega-3 Acid Ethyl Esters (Omega-3 Acid Ethyl Esters) | $21.0M | 239,899 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology